Sidewinder Therapeutics has announced the successful close of an oversubscribed $137 million Series B financing round, marking a significant milestone for the emerging biopharmaceutical company focused on next-generation cancer treatments. The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with continued support from OrbiMed and new participation from major investors including Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments.
Alongside the financing, the company strengthened its leadership with key additions to its Board of Directors, including Daniel Estes, Ph.D., Michal Silverberg, Josh Richardson, M.D., and John Hamer, Ph.D., representing the new and existing investors.
The funding will support Sidewinder Therapeutics in advancing its innovative pipeline of bispecific antibody-drug conjugates (ADCs), a rapidly evolving class of targeted cancer therapies. These next-generation ADCs are designed to precisely target receptor co-complexes found on tumor cells, enabling more effective drug delivery while minimizing damage to healthy tissue.
According to CEO and co-founder Eric Murphy, Ph.D., the company is positioned to capitalize on a turning point in ADC technology. He noted that recent scientific advances have opened new possibilities for bispecific ADCs, allowing for improved targeting and internalization of cancer therapies. Sidewinder aims to leverage these breakthroughs to develop treatments for cancers that currently have limited therapeutic options.
The company’s research focuses on solid tumors, particularly those with high unmet medical need, including squamous cell carcinomas of the lung and head and neck, as well as gastrointestinal cancers such as colorectal cancer. Its approach involves engineering bispecific antibodies from internally discovered sequences that can bind to tumor-specific receptor combinations, enhancing precision and therapeutic impact.
Investors expressed confidence in the company’s scientific approach and potential to address longstanding challenges in the ADC field, particularly around safety and efficacy. With fresh capital and expanded leadership, Sidewinder plans to accelerate development efforts, with its lead program expected to enter clinical trials by 2027.
The successful fundraising underscores growing investor interest in innovative oncology platforms and highlights Sidewinder’s ambition to reshape cancer treatment through next-generation targeted therapies.